Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
<p>Gene expression of major signalling pathways and multiplex immunohistochemical comparison of markers between timepoints and tumor sites. A) Gene expression of related oncogenic signalling pathways between treatment timepoints and site, B) Estimated mean difference of proteins and pathways b...
Sparad:
| Huvudupphovsman: | James S. Wilmott (15008931) (author) |
|---|---|
| Övriga upphovsmän: | Hussein Tawbi (15054769) (author), Johnathan A. Engh (15054772) (author), Nduka M. Amankulor (15054775) (author), Brindha Shivalingam (15054778) (author), Hiya Banerjee (15054781) (author), Ismael A. Vergara (15054784) (author), Hansol Lee (15054787) (author), Peter A. Johansson (15054790) (author), Peter M. Ferguson (15054793) (author), Philippe Saiag (15054796) (author), Caroline Robert (15032672) (author), Jean-Jacques Grob (15054799) (author), Lisa H. Butterfield (15035537) (author), Richard A. Scolyer (10778711) (author), John M. Kirkwood (15023483) (author), Georgina V. Long (11420813) (author), Michael A. Davies (14932995) (author) |
| Publicerad: |
2025
|
| Ämnen: | |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Liknande verk
Liknande verk
-
Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
av: James S. Wilmott (15008931)
Publicerad: (2025) -
Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
av: Qingsheng Xu (17078830)
Publicerad: (2025) -
Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
av: Qingsheng Xu (17078830)
Publicerad: (2025) -
Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
av: Tom Wei-Wu Chen (15053003)
Publicerad: (2025) -
Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
av: Tom Wei-Wu Chen (15053003)
Publicerad: (2025)